You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
十年風雨,利刃出鞘——錦欣生殖(01951.HK)旗下深圳中山泌尿外科醫院生殖免疫科10週年慶典落幕
格隆匯 12-09 18:30

中國,深圳

2020年12月6日

錦欣生殖(01951.HK)旗下深圳中山泌尿外科醫院生殖免疫診療科十週年慶典活動隆重舉行。醫院相關管理層、眾多嘉賓及專家同仁應邀出席。

自2010年建立至今,深圳中山泌尿外科醫院生殖免疫診療科走過十年風雨歷程。從摸索試水到快速成長、從逐漸成熟到業內領先……生殖免疫診療科連若純主任回顧了科室的每一步發展及團隊並肩攻克治療新方向的不懈努力。

生殖免疫診療科深入探究複發性流產和反覆種植失敗的原因,以進一步幫助患者明確病因並制定精準的治療策略。通過剖析疾病發生、發展的關鍵免疫細胞亞羣譜系圖,可以解析免疫、代謝及菌羣三者的相關性及相關分子調控機制,為臨牀提供新的診療思路。此外,根據患者的血液和內膜確定相關的免疫指標和分子標記物,可以構建預測妊娠結局的臨牀決策模型,進而幫助尋找新的治療方案。

深圳中山泌尿外科醫院生殖免疫診療科不僅可提供多達80餘項的生殖免疫專項檢查,而且制定了肝素治療、宮腔灌注等20餘種針對性治療方案。根據免疫指標結果及其他臨牀指標,生殖免疫診療科將患者分為“免疫反應過度”和“免疫反應不足”兩大類,並對免疫異常指標給予針對性治療手段,為每位患者制定更加精確的個體化治療方案;同時,通過及時調整孕期用藥和治療,形成特色有效的免疫狀態評估體系和治療方案,最終保障患者成功生育健康寶寶。

目前,生殖免疫診療科已建立多個臨牀研究平台,包括外周血免疫狀態評估平台、自身抗體譜檢測平台、血栓前狀態評估平台、子宮內膜數字化病理分析平台及免疫細胞分離培養平台等。藉助以上平台,生殖免疫診療科圍繞外周血和子宮內膜免疫狀態進行診斷項目的開發,並率先將免疫評估體系應用於不明原因複發性流產的診療中,填補了傳統檢測方法找不到病因的缺點,為臨牀診斷提供了科學、可靠的依據。

深圳中山泌尿外科醫院董事長、生殖免疫診療科創始人曾勇先生在致辭中表示,感謝中泌的患者,是患者推動了生殖免疫診療科成長的腳步,推動了科室的不斷髮展;感謝生殖免疫診療科的同事,生殖免疫科學研究以及臨牀治療的快速發展,離不開這一羣可敬的同事,離不開他們每一個通宵達旦、廢寢忘食的奮鬥。未來,深圳中山泌尿外科醫院生殖免疫診療科將不斷探索前沿應用,努力創新,力將生殖免疫的精準治療以及精緻監測做到極致。

錦欣醫療聯席CEO、曾任上海市第一婦嬰保健院院長的段濤教授對深圳中山泌尿外科醫院生殖免疫診療科十週年生日表達了美好祝願。在對科室取得的成就給予充分肯定的同時,段濤教授也對生殖免疫診療科未來的發展表達了深厚的期許。他表示,臨牀治療中遇到的疑難問題最終還是會回到科研實驗室,深圳中山泌尿外科醫院的科研實力就是臨牀保胎率的重要保證;相信生殖免疫診療科會一步步解決有關生殖免疫的疑難問題,祝願團隊在未來取得更大的進步,造福更多患者。

十年櫛風沐雨,始終堅守初心;十年篳路藍縷,不忘創新奮鬥。未來,深圳中山泌尿外科醫院生殖免疫診療科將持續秉承錦欣生殖“探索生命奧妙,成就美滿家庭”的企業願景,助力更多患者圓生育夢想。

來源:JXR錦欣生殖

原標題:十年風雨,利刃出鞘——錦欣生殖旗下深圳中山泌尿外科醫院生殖免疫科10週年慶典落幕

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account